

**SAVE THE DATE**

# e-SPACE CRM

**January 22-24, 2021**

**THE FIRST GLOBAL WEB-CONFERENCE ON**

## **THE CARDIO-RENAL-METABOLIC SYNDROME**

- 3 days of digital experience
- 3 time zones
- Live & on demand
- CME credits

**FREE REGISTRATION  
FOR THE LIVE**

Replays on-demand: 95 USD

### **Educational objectives**

- Describe the complex pathophysiological interplay between cardiovascular disease, heart failure, diabetes and kidney disease.
- Recognise the need for a multidisciplinary team approach in the management of patients with patients with cardiac, renal and metabolic comorbidities.
- Analyse the results of recent landmark clinical trials and their implications in clinical practice.
- Review novel pharmacological treatments and medical devices.
- Implement treatment algorithms.

**10 Sessions**

**20 live panel discussion**

**40 talks by international experts**

**e-SPACE**   
Cardio-Renal-Metabolic  
**Global web-Conference**



# PRELIMINARY PROGRAM

Local Time  
**ASIA (Singapore)**

Start 4:30 pm SGT (UTC +8)

## **Session 1: CRM highlights of the year**

Chairs: V. Perkovic, A. Coats, V. Chopra

DAPA-CKD (D. Wheeler)

EMPEROR-Reduced (M. Packer)

FIDELIO-DKD (G. L. Bakris)

SCORED & SOLOIST-WHF (D. L. Bhatt)

**Panel discussion**

### **INDUSTRY SESSION**

## **Session 2: CRM important pathways: an update**

Chairs: C-M Hao, S. Anker, G. Filippatos

Fibrosis (F. Zannad)

Hypertension (M. Böhm)

Autonomic dysfunction (M. A. Konstam) Metabolic

changes in diabetes (M. R. Weir)

**Panel discussion**

## **Session 3: Treatment algorithms**

Chairs: S. Anker, M. Sahay

HFpEF (J. Cleland)

HFrEF (A. J. S. Coats)

Kidney failure (on dialysis) with HF

(D. M. Charytan)

CKD with HF (N. Bansal)

**Panel discussion**

end 9:15 pm

Local Time  
**EUROPE/MIDDLE EAST (Madrid)**

Start 4:30 pm CET (UTC +1)

## **Session 4: SGLT2 inhibition**

Chairs: P. Rossing, J. Butler

SGLT2 – heart or kidney drug?

(G. Filippatos)

Using SGLT2 inhibitors – practical issues incl.  
side effect management (A. Cheng)

Management of diuretics (P. Rossignol)

What's new on the horizon? (S. Anker)

**Panel discussion**

### **INDUSTRY SESSION**

## **Session 5: Other glucose-lowering therapeutic approaches**

Chairs: Y. Handelsman

Metformin (M. J. Davies)

Secretagogues (G. Rosano)

GLP-1 receptor agonists (J. B. Green)

DPP-4 inhibitors (M. Cooper)

**Panel discussion**

end 8 pm

Local Time  
**AMERICAS (Chicago)**

Start 4:30 pm CST (UTC -6)

## **Session 6: Prevention and biomarkers**

Chairs: K. F. Adams, K. Damman

**Assessment of kidney function in heart  
failure (J. Testani)**

**Use of natriuretic peptide for patients with  
heart failure and kidney disease (J. Januzzi)**

**Use of troponin in kidney disease and heart  
failure (L. B. Daniels)**

**Assessment of volume status  
(M. R. Costanzo)**

**Panel discussion**

### **INDUSTRY SESSION**

## **Session 7: Emerging treatment approaches for HF**

Chairs: M. N. Kosiborod, A. Deswal

**Potassium binders (J. Butler)**

**Solutions for FMR and TR - valve insuffi-  
ciency (H. Sievert)**

**New cardiovascular devices –  
from neurostimulation to ultrafiltration  
(W. T. Abraham)**

**Mechanical circulatory support  
(L. W. Stevenson)**

**Panel discussion**

end 8 pm

# PRELIMINARY PROGRAM

Local Time  
**ASIA (Singapore)**

Start 4:30 pm SGT (UTC +8)

## **Session 8: Arrhythmias in kidney disease**

Chairs: D.-C. Tarn, V. Chopra

- AF in kidney disease and its treatment (G. Y. H. Lip)
- SCD in kidney disease and its treatment (W. Zareba)
- Stroke prevention in patients with AF and CKD (W. C. Winkelmayr)
- Arrhythmias in diabetic kidney disease: a cardiology perspective (C. Linde)
- Panel discussion

### **INDUSTRY SESSION**

## **Session 9: HFpEF**

Chairs: A. Coats, G. Filippatos, Y Zhang

- Diagnosis (K. Sharma)
- HFpEF in CKD (W. H. Wilson Tang)
- Treatment part 1 - Drugs (J. J. V. McMurray)
- Treatment part 2 - Devices (G. Hasenfuß)
- Panel discussion

## **Session 10: Anemia and iron deficiency**

Chairs: A. Webster, A. Coats, S. Anker

- Iron deficiency in CKD and HF (A. Hernandez)
- AFFIRM-AHF: more insights (P. Ponikowski)
- IV iron and ESAs in CKD (I. Macdougall)
- HIF PHLs: effects on renal anemia and CV outcomes (A. Levin)
- Panel discussion

end 9:15 pm

Local Time  
**EUROPE/MIDDLE EAST (Madrid)**

Start 4:30 pm CET (UTC +1)

## **Session 3: Treatment algorithms**

Chairs: J. Butler, C. Herzog

- HFpEF (J. Cleland)
- HFrEF (A. J. S. Coats)
- Kidney failure (on dialysis) with HF (D. M. Charytan)
- CKD with HF (N. Bansal)
- Panel discussion

### **INDUSTRY SESSION**

## **Session 1: CRM highlights of the year**

Chairs: G. Rosano, S. Anker

- DAPA-CKD (D. Wheeler)
- EMPEROR-Reduced (M. Packer) FIDE-LIO-DKD (G. L. Bakris)
- SCORED & SOLOIST-WHF (D. L. Bhatt)
- Panel discussion

end 8 pm

Local Time  
**AMERICAS (Chicago)**

Start 4:30 pm CST (UTC -6)

## **Session 2: CRM important pathways: an update**

Chairs: S. Zieroth, M. Fudim

- Fibrosis (F. Zannad)
- Hypertension (M. Böhm)
- Autonomic dysfunction (M. A. Konstam)
- Metabolic changes in diabetes (M. R. Weir)
- Panel discussion

### **INDUSTRY SESSION**

## **Session 4: SGLT2 inhibition**

Chairs: TBD

- SGLT2 – heart or kidney drug? (G. Filippatos)
- Using SGLT2 inhibitors – practical issues incl. side effect management (A. Cheng)
- Management of diuretics (P. Rossignol)
- What's new on the horizon? (S. Anker)
- Panel discussion

end 8 pm

# PRELIMINARY PROGRAM

Local Time  
**ASIA (Singapore)**

Start 4:30 pm SGT (UTC +8)

## **Session 5: Other glucose-lowering therapeutic approaches**

Chairs: J. CN Chan, S. Kalra

**Metformin (M. J. Davies)**

**Secretagogues (G. Rosano)**

**GLP-1 receptor agonists (J. B. Green)**

**DPP-4 inhibitors (M. Cooper)**

**Panel discussion**

### **INDUSTRY SESSION**

## **Session 6: Prevention and biomarkers**

Chairs: S. von Haehling

**Assessment of kidney function in heart failure (J. Testani)**

**Use of natriuretic peptide for patients with heart failure and kidney disease (J. Januzzi)**

**Use of troponin in kidney disease and heart failure (L. B. Daniels)**

**Assessment of volume status (M. R. Costanzo)**

**Panel discussion**

end 9:15 pm

Local Time  
**EUROPE/MIDDLE EAST (Madrid)**

Start 4:30 pm CET (UTC +1)

## **Session 7: Emerging treatment approaches for HF**

Chairs: M. Metra, P. Sharma, G. Filippatos

**Potassium binders (J. Butler)**

**Solutions for FMR and TR - valve insufficiency (H. Sievert)**

**New cardiovascular devices – from neurostimulation to ultrafiltration (W. T. Abraham)**

**Mechanical circulatory support (L. W. Stevenson)**

**Panel discussion**

### **INDUSTRY SESSION**

## **Session 9: HFpEF**

Chairs: S. Anker

**Diagnosis (K. Sharma)**

**HFpEF in CKD (W. H. Wilson Tang)**

**Treatment part 1 - Drugs (J. J. V. McMurray)**

**Treatment part 2 - Devices (G. Hasenfuß)**

**Panel discussion**

end 8 pm

Local Time  
**AMERICAS (Chicago)**

Start 4:30 pm CST (UTC -6)

## **Session 8: Arrhythmias in kidney disease**

Chairs: M. Turakhia, C. Clase, N. Bansal

**AF in kidney disease and its treatment (G. Y. H. Lip)**

**SCD in kidney disease and its treatment (W. Zareba)**

**Stroke prevention in patients with AF and CKD (W. C. Winkelmayer)**

**Arrhythmias in diabetic kidney disease: a cardiology perspective (C. Linde)**

**Panel discussion**

### **INDUSTRY SESSION**

## **Session 10: Anemia and iron deficiency**

Chairs: W. C. Winkelmayer, J. Butler

**Iron deficiency in CKD and HF (A. Hernandez)**

**AFFIRM-AHF: more insights (P. Ponikowski)**

**IV iron and ESAs in CKD (I. Macdougall)**

**HIF PHIs: effects on renal anemia and CV outcomes (A. Levin)**

**Panel discussion**

end 8 pm

# A PANEL OF INTERNATIONAL EXPERTS

## CHAIRS



**Stefan Anker**



**Nisha Bansal**



**Javed Butler**



**Vijay Chopra**



**Andrew Coats**



**Gerasimos  
Filippatos**



**Charles Herzog**



**Giuseppe  
Rosano**



**Wolfgang  
Winkelmayer**

## SESSIONS CHAIRS

Stefan D. Anker  
Kirkwood F. Adams  
Juliana CN Chan  
Catherine Clase  
Kevin Damman  
Anita Deswal  
Kamyar Kalantar-Zadeh  
Sanjay Kalra  
Fudim Marat  
Marco Metra  
Stephan von Haehling  
Yehuda Handelsman  
Chuan-Ming Hao  
S. Harikrishnan  
Mikhail N. Kosiborod  
Vlado Perkovic  
Sharma Purva  
Giuseppe M. C. Rosano  
Peter Rossing  
Manisha Sahay  
Der-Cherng Tarng  
Mintu Turakhia  
Angela Webster  
Yuhui Zhang  
Shelley Zieroth

- 3 days of digital experience
- 3 time zones
- Live & on demand
- CME credits

**FREE REGISTRATION  
FOR THE LIVE**

**Replays on-demand: 95 USD**

Contact  
[info@tmacademy.org](mailto:info@tmacademy.org)  
[tmacademy.org](http://tmacademy.org)

## CONFIRMED FACULTY

William T. Abraham  
Stefan D. Anker  
George L. Bakris  
Nisha Bansal  
Deepak L. Bhatt  
Michael Böhm  
Javed Butler  
David M. Charytan  
Alice Cheng

John Cleland  
Andrew J. S. Coats  
M. Cooper  
Maria Rosa Costanzo  
Lori B. Daniels  
Melanie J. Davies  
Gerasimos Filippatos  
Jennifer B. Green  
Gerd Hasenfuß

Adrian F. Hernandez  
Charles Herzog  
James L. Januzzi  
Marvin A. Konstam  
Adeera Levin  
Cecilia Linde  
Gregory Y. H. Lip  
Iain Macdougall  
John J. V. McMurray

Milton Packer  
Piotr Ponikowski  
Giuseppe M. C. Rosano  
Patrick Rossignol  
Kavita Sharma  
Horst Sievert  
Lynne W. Stevenson  
W. H. Wilson Tang  
Jeffrey Testani

Matthew R. Weir  
David C. Wheeler  
Wolfgang C. Winkelmayer  
Faiez Zannad  
Wojciech Zareba

**e-SPACE**  
Cardio-Renal-Metabolic  
Global web-Conference

